{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:fda:trisenox:0:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Afda%3Atrisenox%3A0%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002198,
    "timestamp_received": "2026-10-16T23:36:00.273827+00:00Z",
    "timestamp_returned": "2026-10-16T23:36:00.276025+00:00Z",
    "trace_id": "ab285652-98ea-47ce-b101-f10d5be50403"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:fda:trisenox:0:0",
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2025-06-26:0",
          "type": "Contribution",
          "description": "Resolving statements mapped to incorrect propositions",
          "date": "2025-06-26",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:vanallenlab:2024-10-30:0",
          "type": "Contribution",
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:fda:2018-01-12:0",
          "type": "Contribution",
          "description": "Indication received traditional approval.",
          "date": "2018-01-12",
          "contributor": {
            "id": "agent:org:fda",
            "type": "Agent",
            "agentType": "organization",
            "name": "Food and Drug Administration",
            "description": "Regulatory agency that approves drugs for use in the United States."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda:trisenox",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Trisenox (arsenic trioxide) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Cephalon, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Trisenox",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "arsenic trioxide",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 21248,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2020-10-20",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        },
        {
          "id": "doc:fda:trisenox:2018-01-12",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Trisenox (arsenic trioxide) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf. Revised January 2018. Accessed October 6, 2026.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Cephalon, Inc.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Trisenox",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "arsenic trioxide",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 21248,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2018-01-12",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Deprecated",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:28",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C3182",
          "conceptType": "Disease",
          "name": "Acute Promyelocytic Leukemia with PML::RARA",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:APLPMLRARA",
                "code": "APLPMLRARA",
                "name": "APL with PML-RARA",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=APL+with+PML-RARA+%28APLPMLRARA%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": false,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C3182",
            "code": "C3182",
            "name": "Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3182"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C1005",
          "conceptType": "Therapy",
          "name": "Arsenic trioxide",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:18330",
                "code": "18330",
                "name": "arsenic trioxide",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=18330"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:1333379",
                "code": "1333379",
                "name": "arsenic trioxide",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1333379"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "PML::RARA inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C1005",
            "code": "C1005",
            "name": "Arsenic Trioxide",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1005"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:79",
                "present": true,
                "subject": {
                  "id": "bmkr:79",
                  "type": "CategoricalVariant",
                  "name": "PML::RARA",
                  "constraints": [
                    {
                      "type": "AdjacencyConstraint",
                      "orderKnown": true,
                      "adjoinedElements": [
                        {
                          "id": "gene:hgnc:9113",
                          "conceptType": "Gene",
                          "name": "PML",
                          "primaryCoding": {
                            "id": "coding:hgnc:9113",
                            "code": "HGNC:9113",
                            "system": "https://genenames.org",
                            "iris": [
                              "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9113"
                            ]
                          },
                          "mappings": [
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ensembl:ensg00000140464",
                                "code": "ENSG00000140464",
                                "system": "https://www.ensembl.org",
                                "iris": [
                                  "https://www.ensembl.org/id/ENSG00000140464"
                                ]
                              }
                            },
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ncbi:5371",
                                "code": "5371",
                                "system": "https://www.ncbi.nlm.nih.gov/gene",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/gene/5371"
                                ]
                              }
                            },
                            {
                              "relation": "relatedMatch",
                              "coding": {
                                "id": "coding:refseq:NM_033238.3",
                                "code": "NM_033238.3",
                                "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/nuccore/NM_033238.3"
                                ]
                              }
                            }
                          ]
                        },
                        {
                          "id": "gene:hgnc:9864",
                          "conceptType": "Gene",
                          "name": "RARA",
                          "primaryCoding": {
                            "id": "coding:hgnc:9864",
                            "code": "HGNC:9864",
                            "system": "https://genenames.org",
                            "iris": [
                              "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9864"
                            ]
                          },
                          "mappings": [
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ensembl:ensg00000131759",
                                "code": "ENSG00000131759",
                                "system": "https://www.ensembl.org",
                                "iris": [
                                  "https://www.ensembl.org/id/ENSG00000131759"
                                ]
                              }
                            },
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ncbi:5914",
                                "code": "5914",
                                "system": "https://www.ncbi.nlm.nih.gov/gene",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/gene/5914"
                                ]
                              }
                            },
                            {
                              "relation": "relatedMatch",
                              "coding": {
                                "id": "coding:refseq:NM_000964.4",
                                "code": "NM_000964.4",
                                "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/nuccore/NM_000964.4"
                                ]
                              }
                            }
                          ]
                        }
                      ]
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Gene fusion"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:fda:trisenox:0",
            "type": "Indication",
            "description": "TRISENOX is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2025-06-26:0",
                "type": "Contribution",
                "description": "Resolving statements mapped to incorrect propositions",
                "date": "2025-06-26",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:vanallenlab:2024-10-30:0",
                "type": "Contribution",
                "description": "Initial access of FDA approvals",
                "date": "2024-10-30",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:fda:2018-01-12:0",
                "type": "Contribution",
                "description": "Indication received traditional approval.",
                "date": "2018-01-12",
                "contributor": {
                  "id": "agent:org:fda",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "Food and Drug Administration",
                  "description": "Regulatory agency that approves drugs for use in the United States."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:fda:trisenox",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Trisenox (arsenic trioxide) [package insert]. FDA.",
                "title": null,
                "aliases": [],
                "description": "Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.",
                "urls": [
                  "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf",
                  "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:fda",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "Food and Drug Administration",
                      "description": "Regulatory agency that approves drugs for use in the United States."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Cephalon, Inc.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Trisenox",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "arsenic trioxide",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": null,
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": 21248,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2020-10-20",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              },
              {
                "id": "doc:fda:trisenox:2018-01-12",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Trisenox (arsenic trioxide) [package insert]. FDA.",
                "title": null,
                "aliases": [],
                "description": "Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf. Revised January 2018. Accessed October 6, 2026.",
                "urls": [
                  "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf",
                  "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:fda",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "Food and Drug Administration",
                      "description": "Regulatory agency that approves drugs for use in the United States."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Cephalon, Inc.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Trisenox",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "arsenic trioxide",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": null,
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": 21248,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2018-01-12",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Deprecated",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}